ENO2

Across TCGA pan-cancer cohorts, ENO2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ENO2 data layer compared with 29 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ENO2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ENO2 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LUAD, COAD, and LSCC are the cancer types where ENO2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.278	0.879	<.001	55	view →
COAD	DFS	Median	All	0.883	1.000	.017	48	view →
LSCC	DFS	Median	All	0.994	0.884	.003	15	view →
PDAC	DFS	Median	III,IV	0.487	0.838	.030	6	view →
HNSC	DFS	Quartile	All	0.461	0.985	.024	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ENO2–LUAD (OS)

Open the LUAD breakdown →